Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Tocilizumab (Primary) ; Prednisone
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Acronyms SEMAPHORE
- 15 Jun 2024 Results(n=33)aiming to assess after the 24th week the relapse rate and markers of patients who received a 6-month TCZ treatment and achieved remission , presented at the 25th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism.
- 03 Jun 2023 Data from this study was used to identify predictive factors of favourable evolution in GC-dependent PMR patients to optimize its management, presented at the 24th Annual Congress of the European League Against Rheumatism.